PL2931738T3 - Kompozycje zawierające cykliczne dinukleotydy purynowe o zdefiniowanej stereochemii i sposoby ich otrzymywania i zastosowania - Google Patents

Kompozycje zawierające cykliczne dinukleotydy purynowe o zdefiniowanej stereochemii i sposoby ich otrzymywania i zastosowania

Info

Publication number
PL2931738T3
PL2931738T3 PL13863379T PL13863379T PL2931738T3 PL 2931738 T3 PL2931738 T3 PL 2931738T3 PL 13863379 T PL13863379 T PL 13863379T PL 13863379 T PL13863379 T PL 13863379T PL 2931738 T3 PL2931738 T3 PL 2931738T3
Authority
PL
Poland
Prior art keywords
compositions
preparation
methods
cyclic purine
purine dinucleotides
Prior art date
Application number
PL13863379T
Other languages
English (en)
Polish (pl)
Inventor
Jr. Thomas W. Dubensky
David B. Kanne
Meredith Lai Ling Leong
Edward Emile Lemmens
Laura Hix Glickman
Original Assignee
Aduro Biotech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aduro Biotech, Inc. filed Critical Aduro Biotech, Inc.
Publication of PL2931738T3 publication Critical patent/PL2931738T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/213—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
PL13863379T 2012-12-13 2013-12-13 Kompozycje zawierające cykliczne dinukleotydy purynowe o zdefiniowanej stereochemii i sposoby ich otrzymywania i zastosowania PL2931738T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261737006P 2012-12-13 2012-12-13
US201361790514P 2013-03-15 2013-03-15
EP13863379.7A EP2931738B1 (en) 2012-12-13 2013-12-13 Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
PCT/US2013/075189 WO2014093936A1 (en) 2012-12-13 2013-12-13 Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use

Publications (1)

Publication Number Publication Date
PL2931738T3 true PL2931738T3 (pl) 2019-07-31

Family

ID=50935019

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13863379T PL2931738T3 (pl) 2012-12-13 2013-12-13 Kompozycje zawierające cykliczne dinukleotydy purynowe o zdefiniowanej stereochemii i sposoby ich otrzymywania i zastosowania

Country Status (18)

Country Link
US (2) US9695212B2 (enExample)
EP (2) EP3527579A1 (enExample)
JP (2) JP6333843B2 (enExample)
KR (1) KR20150095668A (enExample)
CN (2) CN105008381B (enExample)
AU (2) AU2013358892B2 (enExample)
BR (1) BR112015013440B1 (enExample)
CA (1) CA2886456A1 (enExample)
DK (1) DK2931738T3 (enExample)
EA (1) EA201590396A1 (enExample)
ES (1) ES2718910T3 (enExample)
HU (1) HUE043262T2 (enExample)
MX (1) MX361680B (enExample)
PL (1) PL2931738T3 (enExample)
PT (1) PT2931738T (enExample)
SG (2) SG11201502796RA (enExample)
SI (1) SI2931738T1 (enExample)
WO (1) WO2014093936A1 (enExample)

Families Citing this family (181)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2624873T1 (sl) 2010-10-06 2020-07-31 President And Fellows Of Harvard College Injektabilni, pore-formirajoči hidrogeli za celične terapije - na osnovi materialov
NZ702392A (en) * 2012-06-08 2017-03-31 Aduro Biotech Compositions and methods for cancer immunotherapy
WO2014093936A1 (en) 2012-12-13 2014-06-19 Aduro Biotech, Inc. Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
RU2015129030A (ru) 2012-12-19 2017-01-26 Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем Фармацевтическое направленное воздействие на путь передачи сигнала циклических динуклеотидов млекопитающих
MX374828B (es) 2013-04-29 2025-03-06 Memorial Sloan Kettering Cancer Center Composiciones y metodos para alterar la señalizacion del segundo mensajero.
US20140329889A1 (en) * 2013-05-03 2014-11-06 The Regents Of The University Of California Cyclic di-nucleotide induction of type i interferon
US9549944B2 (en) 2013-05-18 2017-01-24 Aduro Biotech, Inc. Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
CU24377B1 (es) 2013-05-18 2018-12-05 Aduro Biotech Inc Dinucléotidos de purina cíclicos y composiciones de los mismos útiles para inducir la producción de interferón de tipo i dependientes de sting
JP6400082B2 (ja) * 2013-05-18 2018-10-03 アデュロ バイオテック，インコーポレイテッド 「インターフェロン遺伝子の刺激因子」依存性シグナル伝達を抑制するための組成物および方法
US10176292B2 (en) 2013-07-31 2019-01-08 Memorial Sloan-Kettering Cancer Center STING crystals and modulators
US20160287623A1 (en) * 2013-11-19 2016-10-06 The University Of Chicago Use of sting agonist as cancer treatment
CN103908468B (zh) * 2014-04-21 2017-02-08 上海捌加壹医药科技有限公司 环二核苷酸cGAMP在制备抗肿瘤药物中的应用
JP7348708B2 (ja) 2014-04-30 2023-09-21 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 組み合わせワクチン装置および癌細胞を殺滅する方法
US10450341B2 (en) 2014-06-04 2019-10-22 Glaxosmithkline Intellectual Property Development Limited Cyclic di-nucleotides as modulators of STING
JP6762030B2 (ja) * 2014-11-20 2020-09-30 国立研究開発法人医薬基盤・健康・栄養研究所 異なる核酸アジュバントの組み合わせによる、新規Ｔｈ１誘導性アジュバントおよびその用途
PL3233882T3 (pl) 2014-12-16 2020-04-30 Kayla Therapeutics Fluorowane cykliczne dinukleotydy do indukcji cytokin
GB201501462D0 (en) 2015-01-29 2015-03-18 Glaxosmithkline Ip Dev Ltd Novel compounds
CA3256526A1 (en) 2015-02-11 2025-10-30 The Johns Hopkins University Bacteria over-expressing c-di-amp and therapeutic methods
BR112017018908A2 (pt) * 2015-03-10 2018-04-17 Aduro Biotech, Inc. composições e métodos para ativar a sinalização dependente do "estimulador do gene de interferon
US11571462B2 (en) 2015-06-03 2023-02-07 The Medical College Of Wisconsin, Inc. Engineered CCL20 locked dimer polypeptide
CA2988086C (en) 2015-06-03 2023-09-19 The Medical College Of Wisconsin, Inc. An engineered ccl20 locked dimer polypeptide
US11453697B1 (en) 2015-08-13 2022-09-27 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
CN108137641B (zh) 2015-08-13 2022-04-01 默沙东公司 作为sting激动剂的环状双核苷酸化合物
MA48579A (fr) 2015-09-01 2020-03-18 Agenus Inc Anticorps anti-pd1 et méthodes d'utilisation de ceux-ci
CN105367617A (zh) * 2015-09-25 2016-03-02 武汉品生科技有限公司 一种基于环二腺核苷酸的衍生物、tat多肽及其在一型干扰素小分子中抑制剂的应用
US10906930B2 (en) 2015-10-28 2021-02-02 Chinook Therapeutics, Inc. Compositions and methods for activating “stimulator of interferon gene”-dependent signalling
CN106539813B (zh) * 2015-11-30 2019-12-03 杭州星鳌生物科技有限公司 干扰素刺激基因(sting)激活剂在抗炎症中的应用
RU2020113165A (ru) 2015-12-03 2020-06-09 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Циклические пуриновые динуклеотиды в качестве модуляторов sting
CN106539814A (zh) * 2015-12-09 2017-03-29 聊城市奥润生物医药科技有限公司 干扰素基因刺激蛋白（sting）激动剂在抗类风湿性关节炎等疾病中的应用
CN106554416B (zh) * 2015-12-09 2019-03-15 聊城市奥润生物医药科技有限公司 一种抗pd-l1人源化单克隆抗体联合干扰素基因刺激蛋白（sting）激动剂在抗肿瘤中的应用
CN106540260A (zh) * 2015-12-09 2017-03-29 聊城市奥润生物医药科技有限公司 干扰素基因刺激蛋白（sting）激动剂在抗阿尔兹海默症中的应用
TWI765875B (zh) 2015-12-16 2022-06-01 美商磨石生物公司 新抗原辨識、製造及用途
WO2017106740A1 (en) * 2015-12-16 2017-06-22 Aduro Biotech, Inc. Methods for identifying inhibitors of "stimulator of interferon gene"-dependent interferon production
PT3402801T (pt) 2016-01-11 2025-10-23 Innate Tumor Immunity Inc Dinucleótidos cíclicos para o tratamento de condições associadas à atividade de sting, tal como cancro
AU2017225769B2 (en) * 2016-03-02 2023-01-05 The Board Of Regents Of The University Of Texas System Sting activating nanovaccine for immunotherapy
HUE060396T2 (hu) 2016-03-18 2023-02-28 Immune Sensor Llc Ciklikus DI-nukleotid vegyületek és azok felhasználási módszerei
CN106539757A (zh) * 2016-03-20 2017-03-29 聊城市奥润生物医药科技有限公司 环二核苷酸cGAMP-脂质体在抗肿瘤中的应用
MX2018012266A (es) 2016-04-07 2019-05-30 Glaxosmithkline Ip Dev Ltd Amidas heterociclicas como moduladores de proteinas.
HUE058932T2 (hu) 2016-04-07 2022-09-28 Glaxosmithkline Ip Dev Ltd Fehérjemodulátorokként hasznos heterociklikus amidok
EP3448393A1 (en) 2016-04-25 2019-03-06 Invivogen Novel complexes of immunostimulatory compounds, and uses thereof
US10696985B1 (en) 2016-06-06 2020-06-30 Vanderbilt University Reversibly crosslinked endosomolytic polymer vesicles for cytosolic drug delivery
EP3507367A4 (en) 2016-07-05 2020-03-25 Aduro BioTech, Inc. CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
JP7100227B2 (ja) * 2016-07-06 2022-07-13 エフ－スター・セラピューティクス・インコーポレイテッド 疾患の治療のための化合物、組成物、および方法
WO2018013924A1 (en) 2016-07-15 2018-01-18 Massachusetts Institute Of Technology Synthetic nanoparticles for delivery of immunomodulatory compounds
DE102016113714A1 (de) 2016-07-26 2018-02-01 Rosa Karl Transfektionsverfahren mit nicht-viralen Genliefersystemen
NL2017267B1 (en) 2016-07-29 2018-02-01 Aduro Biotech Holdings Europe B V Anti-pd-1 antibodies
NL2017270B1 (en) 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
CA3032505A1 (en) 2016-08-02 2018-02-08 President And Fellows Of Harvard College Biomaterials for modulating immune responses
EP3922279B8 (en) 2016-08-30 2025-02-12 Dana-Farber Cancer Institute, Inc. Drug delivery compositions and uses thereof
WO2018053508A1 (en) * 2016-09-19 2018-03-22 The University Of North Carolina At Chapel Hill Methods and compositions for inducing an immune response
US10537590B2 (en) 2016-09-30 2020-01-21 Boehringer Ingelheim International Gmbh Cyclic dinucleotide compounds
RS62410B1 (sr) 2016-10-04 2021-10-29 Merck Sharp & Dohme Benzo[b]tiofenska jedinjenja kao agonisti sting
WO2018065360A1 (de) 2016-10-07 2018-04-12 Biolog Life Science Institute Forschungslabor Und Biochemica-Vertrieb Gmbh Benzimidazolhaltige cyclische dinukleotide, verfahren zu deren herstellung und ihre verwendung zur aktivierung von stimulator von interferongenen (sting)-abhängigen signalwegen
US10266558B2 (en) * 2016-10-07 2019-04-23 Alexandre Vasilievich Ivachtchenko Macroheterocyclic nucleoside derivatives and their analogues, production and use thereof
JOP20170192A1 (ar) 2016-12-01 2019-01-30 Takeda Pharmaceuticals Co داي نوكليوتيد حلقي
AU2017373945B2 (en) 2016-12-07 2025-01-23 Agenus Inc. Antibodies and methods of use thereof
WO2018119117A1 (en) * 2016-12-22 2018-06-28 The Regents Of The University Of California Methods of producing cyclic dinucleotides
US20200055883A1 (en) * 2017-02-17 2020-02-20 Eisai R&D Management Co., Ltd. Cyclic di-nucleotides derivative for the treatment of cancer
JP2018131427A (ja) * 2017-02-17 2018-08-23 国立研究開発法人理化学研究所 免疫細胞の制御技術
CA3053568A1 (en) 2017-02-21 2018-08-30 Board Of Regents, The University Of Texas System Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling
CN106928298B (zh) * 2017-03-13 2021-10-22 杭州星鳌生物科技有限公司 环二核苷酸cGAMP衍生物的结构组成、制备方法及其在抗肿瘤中的应用
JOP20190218A1 (ar) 2017-03-22 2019-09-22 Boehringer Ingelheim Int مركبات ثنائية النيوكليوتيدات حلقية معدلة
TW202430219A (zh) 2017-04-13 2024-08-01 荷蘭商賽羅帕公司 抗-SIRPα 抗體
CN110770345A (zh) 2017-04-14 2020-02-07 托尔奈公司 免疫调节多核苷酸、抗体缀合物及其使用方法
AR113224A1 (es) 2017-04-28 2020-02-19 Novartis Ag Conjugados de anticuerpo que comprenden un agonista de sting
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
US11466047B2 (en) 2017-05-12 2022-10-11 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
US11969499B2 (en) 2017-06-16 2024-04-30 William Marsh Rice University Hydrogel delivery of sting immunotherapy for treatment cancer
MA49773A (fr) 2017-08-04 2021-04-21 Merck Sharp & Dohme Combinaisons d'antagonistes de pd-1 et d'agonistes de sting benzo[b
CA3071538A1 (en) 2017-08-04 2019-02-07 Merck Sharp & Dohme Corp. Benzo[b]thiophene sting agonists for cancer treatment
AU2018323053A1 (en) 2017-08-30 2020-03-19 Beijing Xuanyi Pharmasciences Co., Ltd Cyclic di-nucleotides as stimulator of interferon genes modulators
EP3675859A4 (en) 2017-08-31 2021-06-30 Sperovie Biosciences, Inc. COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF A DISEASE
US11707531B2 (en) 2017-09-11 2023-07-25 F-star Therapeutics, Inc. Compounds, compositions, and methods for the treatment of disease
WO2019051488A1 (en) 2017-09-11 2019-03-14 Sperovie Biosciences, Inc. COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE
JP7654240B2 (ja) 2017-09-19 2025-04-01 マサチューセッツ インスティテュート オブ テクノロジー キメラ抗原受容体ｔ細胞治療のための組成物およびその使用
WO2019069270A1 (en) 2017-10-05 2019-04-11 Glaxosmithkline Intellectual Property Development Limited GENERATOR STIMULATOR MODULATORS (STING) INTERFERON
WO2019069269A1 (en) 2017-10-05 2019-04-11 Glaxosmithkline Intellectual Property Development Limited INTERFERON GENE STIMULATOR MODULATORS USEFUL IN THE TREATMENT OF HIV
WO2019075112A1 (en) 2017-10-10 2019-04-18 Gritstone Oncology, Inc. IDENTIFICATION OF NEO-ANTIGENS USING HOT POINTS
KR20200098511A (ko) 2017-11-10 2020-08-20 다케다 야쿠힌 고교 가부시키가이샤 Sting 조절제 화합물, 및 제조 및 사용 방법
US11673891B2 (en) 2017-11-14 2023-06-13 Dana-Farber Cancer Institute, Inc. Imidazopyrimidine compounds and uses thereof
US11730810B2 (en) 2017-11-14 2023-08-22 Children's Medical Center Corporation Composition comprising an antigen and a substituted imidazo[1,2-a]pyrimidine for enhancing human immune response
AU2018373154B2 (en) 2017-11-22 2025-08-07 Seattle Project Corp. Reducing junction epitope presentation for neoantigens
CN111511754B (zh) 2017-12-20 2023-09-12 捷克共和国有机化学与生物化学研究所 活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸
AU2018392213B2 (en) 2017-12-20 2021-03-04 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein
WO2019125974A1 (en) 2017-12-20 2019-06-27 Merck Sharp & Dohme Corp. Cyclic di-nucleotide compounds as sting agonists
US12065649B2 (en) 2018-01-09 2024-08-20 Vanderbilt University Pattern recognition receptor agonist prodrugs and methods of use thereof
US12220462B1 (en) 2018-02-13 2025-02-11 Abionyx Pharma Sa Complexes for delivery of cyclic dinucleotides
WO2019161171A1 (en) * 2018-02-16 2019-08-22 Sperovie Biosciences, Inc. Nanoparticle formulations of sting agonists
MX2020009796A (es) 2018-03-23 2021-01-15 Codiak Biosciences Inc Vesiculas extracelulares que comprenden agonista de estimulador de genes de interferon (sting).
JP2021519270A (ja) 2018-03-27 2021-08-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ２−アザ−ヒポキサンチンまたは６ｈ−ピラゾロ［１，５−ｄ］［１，２，４］トリアジン−７−オンをｓｔｉｎｇアゴニストとして含む環式ジヌクレオチド化合物
US20210024567A1 (en) 2018-03-27 2021-01-28 Boehringer Ingelheim International Gmbh Modified cyclic dinucleotide compounds
US11702430B2 (en) 2018-04-03 2023-07-18 Merck Sharp & Dohme Llc Aza-benzothiophene compounds as STING agonists
EP3774764A1 (en) 2018-04-03 2021-02-17 Merck Sharp&Dohme Corp. Benzothiophenes and related compounds as sting agonists
US11874276B2 (en) 2018-04-05 2024-01-16 Dana-Farber Cancer Institute, Inc. STING levels as a biomarker for cancer immunotherapy
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 ２，２，─環二核苷酸
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TW202014193A (zh) 2018-05-03 2020-04-16 捷克科學院有機化學與生物化學研究所 包含碳環核苷酸之2’3’－環二核苷酸
GB201807924D0 (en) 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
MA52754A (fr) 2018-05-25 2021-04-14 Incyte Corp Composés hétérocycliques tricycliques en tant qu'activateurs de sting
KR20210015937A (ko) 2018-06-01 2021-02-10 에자이 알앤드디 매니지먼트 가부시키가이샤 방광암을 치료하기 위한 방법
WO2020014127A1 (en) 2018-07-10 2020-01-16 Sperovie Biosciences, Inc. Compounds, compositions, and methods for the treatment of disease
WO2020028566A1 (en) 2018-07-31 2020-02-06 Incyte Corporation Heteroaryl amide compounds as sting activators
WO2020028565A1 (en) 2018-07-31 2020-02-06 Incyte Corporation Tricyclic heteraryl compounds as sting activators
TW202019468A (zh) 2018-08-03 2020-06-01 國立大學法人東京大學 誘導細胞性免疫之經鼻疫苗
CA3099904A1 (en) 2018-08-16 2020-02-20 Eisai R&D Management Co., Ltd. Salts of compounds and crystals thereof
MA53438A (fr) 2018-08-24 2021-09-15 Codiak Biosciences Inc Vésicules extracellulaires ciblant des cellules dendritiques et utilisations associées
PT3848054T (pt) 2018-09-06 2025-04-03 Daiichi Sankyo Co Ltd Conjugados anticorpo-fármaco de derivados de dinucleótidos cíclicos
US20220031825A1 (en) * 2018-09-17 2022-02-03 Quratis Inc. Immunological adjuvant and vaccine composition including sting agonist
BR112021005208A2 (pt) 2018-09-21 2021-06-08 Shanghai De Novo Pharmatech Co., Ltd. análogo de dinucleotídeo cíclico, composição farmacêutica do mesmo, e aplicação
US11110106B2 (en) 2018-10-29 2021-09-07 Venenum Biodesign, LLC Sting agonists for treating bladder cancer and solid tumors
WO2020092127A1 (en) 2018-10-29 2020-05-07 Venenum Biodesign, LLC Novel sting agonists
US12508233B2 (en) 2018-10-30 2025-12-30 Vanderbilt University Graft copolymers, methods of forming graft copolymers, and methods of use thereof
WO2020092617A1 (en) 2018-10-31 2020-05-07 Novartis Ag Dc-sign antibody conjugates comprising sting agonists
US11596692B1 (en) 2018-11-21 2023-03-07 Incyte Corporation PD-L1/STING conjugates and methods of use
US12129267B2 (en) 2019-01-07 2024-10-29 Incyte Corporation Heteroaryl amide compounds as sting activators
WO2020143740A1 (zh) * 2019-01-10 2020-07-16 南开大学 环二核苷酸前药分子及其制备方法和应用
US12318403B2 (en) 2019-03-07 2025-06-03 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2′3′-cyclic dinucleotides and prodrugs thereof
WO2020178770A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
US11766447B2 (en) 2019-03-07 2023-09-26 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
EP3941528A1 (en) 2019-03-21 2022-01-26 Codiak BioSciences, Inc. Extracellular vesicle conjugates and uses thereof
PH12021552223A1 (en) 2019-03-21 2022-05-30 Codiak Biosciences Inc Extracellular vesicles for vaccine delivery
EP4671268A2 (en) 2019-03-21 2025-12-31 Lonza Sales AG METHOD FOR PREPARING EXTRACELLULAR VESICLES
US12281109B2 (en) 2019-04-04 2025-04-22 Merck Sharp & Dohme Llc Inhibitors of histone deacetylase-3 useful for the treatment of cancer, inflammation, neurodegeneration diseases and diabetes
TW202104214A (zh) 2019-04-05 2021-02-01 英商葛蘭素史密斯克藍智慧財產發展有限公司 化合物
MA55805A (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc Métodes de modulation de l'activité immunitaire
JP7621974B2 (ja) 2019-05-09 2025-01-27 アリゴス セラピューティクス インコーポレイテッド Ｓｔｉｎｇモジュレータとしての修飾環状ジヌクレオシド化合物
CN114173824A (zh) 2019-05-10 2022-03-11 武田药品工业株式会社 抗体药物缀合物
EP3994158A1 (en) 2019-07-03 2022-05-11 Codiak BioSciences, Inc. Extracellular vesicles targeting t cells and uses thereof
GB201910304D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
GB201910305D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
AU2020324388A1 (en) 2019-08-02 2022-02-24 Mersana Therapeutics, Inc. Bis-[N-((5-carbamoyl)-1H-benzo[d]imidazol-2-yl)-pyrazol-5-carboxamide] derivatives and related compounds as STING (Stimulator of Interferon Genes) agonists for the treatment of cancer
KR20220061977A (ko) 2019-08-12 2022-05-13 퓨리노미아 바이오테크, 아이엔씨. Cd39 발현 세포의 adcc 표적화를 통해 t 세포 매개 면역 반응을 촉진 및 강화하기 위한 방법 및 조성물
WO2021041532A1 (en) 2019-08-26 2021-03-04 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling
EP3785719A1 (en) * 2019-08-28 2021-03-03 Helmholtz-Zentrum für Infektionsforschung GmbH New use of cyclic dinucleotides
AU2020351729A1 (en) 2019-09-25 2022-04-21 Lonza Sales Ag STING agonist comprising exosomes combined with IL-12 displaying exosomes for treating a tumour
US20230103726A1 (en) 2019-09-25 2023-04-06 Codiak Biosciences, Inc. Methods of producing extracellular vesicles
US20230241089A1 (en) 2019-09-25 2023-08-03 Codiak Biosciences, Inc. Sting agonist comprising exosomes for treating neuroimmunological disorders
BR112022005614A2 (pt) 2019-09-25 2022-07-12 Codiak Biosciences Inc Composições de vesícula extracelular
WO2021074695A1 (en) 2019-10-16 2021-04-22 Avacta Life Sciences Limited PD-L1 INHIBITOR - TGFβ INHIBITOR BISPECIFIC DRUG MOIETIES.
WO2021113679A1 (en) 2019-12-06 2021-06-10 Mersana Therapeutics, Inc. Dimeric compounds as sting agonists
WO2021119753A1 (en) 2019-12-18 2021-06-24 Ctxt Pty Limited Compounds
US12251449B2 (en) 2019-12-19 2025-03-18 William Marsh Rice University Synthetic multidomain peptide biomaterials that inhibit inducible nitric oxide synthase
KR20220119085A (ko) 2019-12-20 2022-08-26 남미 테라퓨틱스, 인크. 암의 치료에 유용한 톨-유사 수용체 (“tlr”) 효능제 전구약물을 함유하는 제제화된 및/또는 공동-제제화된 리포솜 조성물 및 그의 방법
JP7735291B2 (ja) 2020-02-21 2025-09-08 エーアールエス ファーマシューティカルズ、インコーポレイテッド ネクチン－４抗体コンジュゲートおよびその使用
EP4110830A4 (en) 2020-02-28 2024-09-11 Tallac Therapeutics, Inc. TRANSGLUTAMINASE-MEDIATED CONJUGATION
KR20220151630A (ko) 2020-03-06 2022-11-15 다이이찌 산쿄 가부시키가이샤 신규 고리형 디뉴클레오티드 유도체를 포함하는 항체 약물 컨쥬게이트
EP4117717A1 (en) 2020-03-13 2023-01-18 Codiak BioSciences, Inc. Extracellular vesicles for treating neurological disorders
AU2021236763A1 (en) 2020-03-20 2022-10-06 Lonza Sales Ag Extracellular vesicles for therapy
MX2022012304A (es) 2020-04-02 2022-11-30 Mersana Therapeutics Inc Conjugados de anticuerpo-farmaco que comprenden agonistas de sting.
JPWO2021206158A1 (enExample) 2020-04-10 2021-10-14
WO2021216572A1 (en) 2020-04-20 2021-10-28 Massachusetts Institute Of Technology Lipid compositions for delivery of sting agonist compounds and uses thereof
US20210340524A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
WO2021221782A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Chimeric antigen receptor-targeting ligands and uses thereof
US12390537B2 (en) 2020-05-13 2025-08-19 Massachusetts Institute Of Technology Compositions of polymeric microdevices and methods of use thereof in cancer immunotherapy
WO2021237100A1 (en) 2020-05-21 2021-11-25 Codiak Biosciences, Inc. Methods of targeting extracellular vesicles to lung
CA3183993A1 (en) 2020-07-01 2022-01-06 Peter R. Baum Anti-asgr1 antibody conjugates and uses thereof
WO2022050300A1 (ja) 2020-09-02 2022-03-10 第一三共株式会社 新規エンド－β－Ｎ－アセチルグルコサミニダーゼ
CA3193107A1 (en) 2020-09-23 2022-03-31 Codiak Biosciences, Inc. Process for preparing extracellular vesicles
US20240241020A1 (en) 2020-09-23 2024-07-18 Lonza Sales Ag Process for preparing extracellular vesicles
US20240082389A1 (en) 2020-09-23 2024-03-14 Lonza Sales Ag Methods of producing extracellular vesicles
WO2022066883A1 (en) 2020-09-23 2022-03-31 Codiak Biosciences, Inc. Extracellular vesicles comprising kras antigens and uses thereof
WO2022079175A1 (en) 2020-10-14 2022-04-21 Boehringer Ingelheim International Gmbh Combination of a sting agonist and a complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist
WO2022083584A1 (zh) * 2020-10-20 2022-04-28 泰励生物科技（上海）有限公司 多功能环二核苷酸及其用途
IL302390A (en) 2020-11-09 2023-06-01 Takeda Pharmaceuticals Co Drug antibody conjugates
WO2022133288A1 (en) 2020-12-17 2022-06-23 Trustees Of Tufts College Fap-activated radiotheranostics, and uses related thereto
EP4032545A1 (en) * 2021-01-26 2022-07-27 Medizinische Hochschule Hannover Immunogenic composition and vaccine containing chlamydia ssp. surface antigens and its use
EP4326321A1 (en) 2021-04-20 2024-02-28 Institut Curie Compositions and methods for use in immunotherapy
EP4326769A1 (en) 2021-04-20 2024-02-28 Institut Curie Compositions and methods for use in immunotherapy
WO2022234003A1 (en) 2021-05-07 2022-11-10 Avacta Life Sciences Limited Cd33 binding polypeptides with stefin a protein
WO2023056468A1 (en) 2021-09-30 2023-04-06 Codiak Biosciences, Inc. Extracellular vesicle comprising cholesterol tagged sting-agonist
US20250243277A1 (en) 2021-10-07 2025-07-31 Avacta Life Sciences Limited Pd-l1 binding affimers
IL315341A (en) 2022-03-02 2024-10-01 Daiichi Sankyo Co Ltd METHOD FOR PRODUCING Fc-CONTAINING MOLECULE
JP2025509191A (ja) 2022-03-04 2025-04-11 マサチューセッツ インスティテュート オブ テクノロジー 経粘膜性の両親媒性物質－タンパク質コンジュゲートワクチン
WO2023218243A1 (en) 2022-05-12 2023-11-16 Avacta Life Sciences Limited Lag-3/pd-l1 binding fusion proteins
EP4569129A1 (en) * 2022-08-10 2025-06-18 Aldevron, LLC Methods for producing cyclic dinucleotides
CN115381936A (zh) * 2022-08-29 2022-11-25 福建师范大学 一种猴痘病毒疫苗
EP4582106A1 (en) 2022-08-29 2025-07-09 Daiichi Sankyo Company, Limited Antibody-drug conjugate including mutant fc region
WO2024199359A1 (zh) * 2023-03-28 2024-10-03 江苏瑞科生物技术股份有限公司 包含环二核苷酸分子的脂质体佐剂系统及其制备方法
WO2024211577A1 (en) 2023-04-05 2024-10-10 Massachusetts Institute Of Technology Hybrid polymeric systems and methods of use thereof
CN116392585A (zh) * 2023-04-06 2023-07-07 中山大学孙逸仙纪念医院 一种肿瘤疫苗佐剂及其应用

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9110808D0 (en) 1991-05-17 1991-07-10 Retroscreen Ltd Aids vaccine and method for its production
GB2257704B (en) * 1991-07-18 1995-03-01 Erba Carlo Spa Cyclic oligonucleotides phosphorothioates
US5904920A (en) 1991-10-04 1999-05-18 Whitehead Institute For Biomedical Research Regulation of systemic immune responses utilizing cytokines and antigens
US5637483A (en) 1991-10-04 1997-06-10 Whitehead Institute For Biomedical Research Irradiated tumor cell vaccine engineered to express GM-CSF
IT1262895B (it) 1992-03-02 1996-07-22 Proteina estratta da ceppi citotossici di helicobacter pylori, gene che la esprime, uso della proteina come vaccino o diagnostico.
US5635160A (en) 1995-06-07 1997-06-03 The University Of North Carolina At Chapel Hill Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions
US6033674A (en) 1995-12-28 2000-03-07 Johns Hopkins University School Of Medicine Method of treating cancer with a tumor cell line having modified cytokine expression
US6277368B1 (en) 1996-07-25 2001-08-21 The Regents Of The University Of California Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine
EP1053301B1 (en) 1998-02-02 2004-04-21 The Johns Hopkins University School Of Medicine A universal immunomodulatory cytokine-expressing bystander cell line and related compositions and methods of manufacture and use
RU2238279C2 (ru) 1999-02-15 2004-10-20 Ниппон Синяку Ко., Лтд. Полинуклеотид с укороченной цепью и способ его получения
US6558670B1 (en) * 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
AU2001290860A1 (en) 2000-09-21 2002-04-02 The Regents Of The University Of California Spas-1 cancer antigen
IL155282A0 (en) * 2000-10-18 2003-11-23 Glaxosmithkline Biolog Sa Vaccines
WO2002059575A2 (en) 2001-01-23 2002-08-01 The Trustees Of Princeton University, Princeton University Method and apparatus for analysis of biological solutions
TW200303759A (en) 2001-11-27 2003-09-16 Schering Corp Methods for treating cancer
AR040996A1 (es) 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
WO2005030186A2 (en) 2003-07-28 2005-04-07 Univ Maryland Method for attenuating virulence of microbial pathogens and for inhibiting microbial biofilm formation
EP1682173A4 (en) 2003-10-15 2007-10-31 Medimmune Inc EPHA2 VACCINE ON LISTERIA BASE
EP1677765A1 (en) * 2003-10-24 2006-07-12 Alza Corporation Preparation of lipid particles
US7592326B2 (en) 2004-03-15 2009-09-22 Karaolis David K R Method for stimulating the immune, inflammatory or neuroprotective response
JP4931798B2 (ja) * 2004-03-15 2012-05-16 ケイ．アール． カラオリス，デイヴィッド 免疫、炎症または神経保護応答のための方法
EP1888790A2 (en) 2005-05-06 2008-02-20 The Regents of the University of California Microfluidic system for identifying or sizing individual particles passing through a channel
US20070059683A1 (en) 2005-09-15 2007-03-15 Tom Barber Veterinary diagnostic system
EP1782826A1 (en) 2005-11-08 2007-05-09 GBF Gesellschaft für Biotechnologische Forschung mbH PQS and c-diGMP and its conjugates as adjuvants and their uses in pharmaceutical compositions
ES2548240T3 (es) 2005-12-01 2015-10-15 Pronai Therapeutics, Inc. Terapias para el cáncer y composiciones farmacéuticas usadas en las mismas
CA2659301A1 (en) 2006-07-28 2008-02-07 Applera Corporation Dinucleotide mrna cap analogs
US20080076778A1 (en) 2006-09-05 2008-03-27 Bipar Sciences, Inc. Methods for designing parp inhibitors and uses thereof
TWI444384B (zh) * 2008-02-20 2014-07-11 Gilead Sciences Inc 核苷酸類似物及其在治療惡性腫瘤上的用途
JP2011529708A (ja) 2008-08-04 2011-12-15 ユニバーシティ オブ マイアミ 自然免疫応答の調節因子ｓｔｉｎｇ（インターフェロン遺伝子の刺激因子）
US8840881B2 (en) 2008-08-28 2014-09-23 Aduro Gvax Inc. Methods and compositions for treating prostate cancer or inducing a humoral immune response against prostate cancer
ES2481040T3 (es) * 2008-12-09 2014-07-29 Coley Pharmaceutical Group, Inc. Oligonucleótidos inmunoestimulantes
CA2754896C (en) 2009-03-09 2017-11-28 Molecular Express, Inc. Methods and compositions for liposomal formulation of antigens and uses thereof
US8414630B2 (en) 2009-03-10 2013-04-09 Marc Evan Richelsoph Active bone screw
PT2437753T (pt) 2009-06-05 2016-11-23 Infectious Disease Res Inst Adjuvantes lipídicos de glucopiranosilo sintéticos e composições de vacina contendo os mesmos
WO2011003025A1 (en) 2009-07-01 2011-01-06 Rutgers, The State University Of New Jersey Synthesis of cyclic diguanosine monophosphate and thiophosphate analogs thereof
US8771933B2 (en) 2009-10-06 2014-07-08 Massachusetts Institute Of Technology Continuous-flow deformability-based cell separation
BR112012014760A2 (pt) * 2009-12-18 2016-06-14 Novartis Ag "composições orgânicas para tratar doenças relacionadas a hsf1, bem como seu uso"
EP2361911A1 (en) * 2010-02-18 2011-08-31 GenKyoTex SA Pyrazolo piperidine derivatives as NADPH oxidase inhibitors
US20110293558A1 (en) 2010-03-22 2011-12-01 Massachusetts Institute Of Technology Material properties of t cells and related methods and compositions
CN102199183B (zh) 2010-03-26 2013-12-18 北京大学 环二鸟苷酸及其类似物和制备方法
CA2798074A1 (en) 2010-04-27 2011-11-03 The Johns Hopkins University Immunogenic compositions and methods for treating neoplasia
US8450293B2 (en) 2010-08-10 2013-05-28 Rutgers, The State University Of New Jersey Synthesis and characterization of C8 analogs of c-di-GMP
SMT201800444T1 (it) 2010-11-17 2018-09-13 Aduro Biotech Inc Metodi e composizioni per indurre una risposta immunitaria contro egfrviii
US9061048B2 (en) 2010-12-15 2015-06-23 The Regents Of The University Of California Cyclic di-AMP induction of type I interferon
EP2655392B1 (en) 2010-12-22 2018-04-18 Alios Biopharma, Inc. Cyclic nucleotide analogs
JP5990256B2 (ja) 2011-04-15 2016-09-07 ザ ユニバーシティ オブ ブリティッシュ コロンビアＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｂｒｉｔｉｓｈ Ｃｏｌｕｍｂｉａ 粒子分離の方法および装置
WO2013086331A1 (en) 2011-12-07 2013-06-13 President And Fellows Of Harvard College High efficiency di-nucleotide cyclase
KR20150004416A (ko) 2012-04-30 2015-01-12 글렌 엔. 바버 면역 반응의 조절
NZ702392A (en) 2012-06-08 2017-03-31 Aduro Biotech Compositions and methods for cancer immunotherapy
CN112587658A (zh) * 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
US9090646B2 (en) 2012-12-05 2015-07-28 Rutgers, The State University Of New Jersey Biotinylated compounds
WO2014093936A1 (en) 2012-12-13 2014-06-19 Aduro Biotech, Inc. Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
RU2015129030A (ru) 2012-12-19 2017-01-26 Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем Фармацевтическое направленное воздействие на путь передачи сигнала циклических динуклеотидов млекопитающих
MX374828B (es) 2013-04-29 2025-03-06 Memorial Sloan Kettering Cancer Center Composiciones y metodos para alterar la señalizacion del segundo mensajero.
US20140329889A1 (en) 2013-05-03 2014-11-06 The Regents Of The University Of California Cyclic di-nucleotide induction of type i interferon
JP6400082B2 (ja) 2013-05-18 2018-10-03 アデュロ バイオテック，インコーポレイテッド 「インターフェロン遺伝子の刺激因子」依存性シグナル伝達を抑制するための組成物および方法
US9549944B2 (en) 2013-05-18 2017-01-24 Aduro Biotech, Inc. Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
CU24377B1 (es) 2013-05-18 2018-12-05 Aduro Biotech Inc Dinucléotidos de purina cíclicos y composiciones de los mismos útiles para inducir la producción de interferón de tipo i dependientes de sting
US10176292B2 (en) 2013-07-31 2019-01-08 Memorial Sloan-Kettering Cancer Center STING crystals and modulators
HK1223794A1 (zh) 2013-10-21 2017-08-11 德雷克塞尔大学 治疗慢性乙型肝炎病毒感染的sting激动剂的用途
US20160287623A1 (en) 2013-11-19 2016-10-06 The University Of Chicago Use of sting agonist as cancer treatment
CA2931146C (en) 2013-11-22 2022-06-28 Brock University Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants
WO2015085565A1 (en) 2013-12-13 2015-06-18 Qualcomm Incorporated Methods and apparatus for cell selection in a wireless communication system
WO2015108595A1 (en) 2014-01-15 2015-07-23 Nikolai Khodarev Anti-tumor therapy
US10450341B2 (en) 2014-06-04 2019-10-22 Glaxosmithkline Intellectual Property Development Limited Cyclic di-nucleotides as modulators of STING
PL3233882T3 (pl) 2014-12-16 2020-04-30 Kayla Therapeutics Fluorowane cykliczne dinukleotydy do indukcji cytokin
GB201501462D0 (en) 2015-01-29 2015-03-18 Glaxosmithkline Ip Dev Ltd Novel compounds
BR112017018908A2 (pt) * 2015-03-10 2018-04-17 Aduro Biotech, Inc. composições e métodos para ativar a sinalização dependente do "estimulador do gene de interferon
CN108137641B (zh) 2015-08-13 2022-04-01 默沙东公司 作为sting激动剂的环状双核苷酸化合物
RU2020113165A (ru) 2015-12-03 2020-06-09 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Циклические пуриновые динуклеотиды в качестве модуляторов sting

Also Published As

Publication number Publication date
JP2018135367A (ja) 2018-08-30
HUE043262T2 (hu) 2019-08-28
US9695212B2 (en) 2017-07-04
JP6704012B2 (ja) 2020-06-03
AU2013358892B2 (en) 2018-06-21
JP2016503029A (ja) 2016-02-01
CN105008381A (zh) 2015-10-28
CN108542913A (zh) 2018-09-18
BR112015013440B1 (pt) 2020-12-08
WO2014093936A1 (en) 2014-06-19
EA201590396A1 (ru) 2015-12-30
SG10201704611WA (en) 2017-07-28
MX2015007447A (es) 2015-12-09
NZ707561A (en) 2020-11-27
CN105008381B (zh) 2018-08-07
US20170283454A1 (en) 2017-10-05
AU2018203682A1 (en) 2018-06-14
JP6333843B2 (ja) 2018-05-30
CA2886456A1 (en) 2014-06-19
US20140205653A1 (en) 2014-07-24
SI2931738T1 (sl) 2019-05-31
DK2931738T3 (en) 2019-04-15
ES2718910T3 (es) 2019-07-05
AU2018203682B2 (en) 2020-07-02
BR112015013440A2 (pt) 2017-07-11
EP2931738A1 (en) 2015-10-21
EP2931738B1 (en) 2019-02-06
KR20150095668A (ko) 2015-08-21
HK1212707A1 (zh) 2016-06-17
EP3527579A1 (en) 2019-08-21
US10414789B2 (en) 2019-09-17
EP2931738A4 (en) 2016-04-27
SG11201502796RA (en) 2015-05-28
PT2931738T (pt) 2019-04-10
AU2013358892A1 (en) 2015-05-21
MX361680B (es) 2018-12-13

Similar Documents

Publication Publication Date Title
SG10201704611WA (en) Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
IL238984A0 (en) Prostacilin preparations and methods of using them
ZA201408594B (en) Xylitol-based anti-mucosal compositions and related methods and compositions
IL252566A0 (en) Pharmacy preparations and methods
EP2680837A4 (en) COMPOSITIONS AND METHODS COMPRISING C16: 1N7-PALMITOLATE
HUE044816T2 (hu) Készítmények és eljárások hajhullás kezelésére
GB201220354D0 (en) Dermal compositions
EP2855769A4 (en) PAPER-MOUCHOIR COMPRISING MACROALGUES
ZA201500450B (en) Novel rebamipide prodrugs, preparation method and use thereof
IL239192A0 (en) Compounds containing vortioxetine and donepezil
IL234695B (en) Antigen compositions and methods
ZA201408674B (en) Oligonucleotide chelate complex-polypeptide compositions and methods
ZA201500692B (en) Benzodioxole derivative and preparation method and use thereof
GB201315350D0 (en) Methods and compositions
EP2938348A4 (en) ALGINATE COMPOSITIONS AND USES THEREOF
GB201315347D0 (en) Methods and compositions
ZA201308892B (en) Compositions and methods
PL2893027T3 (pl) Kompozycje o poprawionej stabilności matrycy i sposoby
GB201208315D0 (en) Pharmaceutical methods and compositions
SG11201502069SA (en) Beta-hydroxy-beta-methylbutryic acid- containing compositions and uses thereof
IL239706A0 (en) Preparations containing alginate and their uses
GB201116340D0 (en) Compositions and methods
GB201213246D0 (en) Cleaning preparation and method
GB201121663D0 (en) Process and compositions